Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.47 |
| ▸ | DRD3 | P35462 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201494 | 0.89 | DRD2 (0.57) | DRD3DRD2DRD4DRD1 | |
| SCHEMBL29438671 | 0.87 | PRMT5 (0.51) | PRMT5WDR77ITGB3ITGA2BDRD3 | |
| SCHEMBL471627 | 0.87 | PRMT5 (0.51) | PRMT5WDR77ITGB3ITGA2BDRD3 | |
| SCHEMBL25899235 | 0.85 | GRM5 (0.58) | PRMT5WDR77ITGB3ITGA2BDRD3 | |
| SCHEMBL7125843 | 0.83 | AOC3 (0.53) | PRMT5WDR77ITGB3ITGA2BDRD3 | |
| SCHEMBL3655756 | 0.83 | PRMT5 (0.53) | PRMT5WDR77ITGB3ITGA2BDRD3 | |
| SCHEMBL7788827 | 0.82 | ITGB3 (0.69) | ITGB3ITGA2BAOC3 | |
| SCHEMBL3655326 | 0.82 | PRMT5 (0.50) | PRMT5WDR77ITGB3ITGA2BDRD3 | |
| SCHEMBL380250 | 0.81 | DRD3 (0.53) | PRMT5WDR77ITGB3ITGA2BDRD3 | |
| SCHEMBL22713731 | 0.81 | AOC3 (0.68) | PRMT5WDR77ITGB3ITGA2BAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-7524842-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524842-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | PRMT5 3292/4885WDR77 4635/4885ITGB3 1884/4885 |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | PRMT5 3292/4885WDR77 4635/4885ITGB3 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.